Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Additional Information (Detail)

v3.22.2
Research and Development Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 31, 2021
Feb. 28, 2021
Sep. 30, 2018
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Research And Development Collaboration Agreements [Line Items]                  
Research and development revenue recognized       $ 4,417,000     $ 15,134,000 $ 12,903,000 $ 18,354,000
Revenue from grant       4,417,000     $ 15,134,000 12,903,000 18,354,000
Grant                  
Research And Development Collaboration Agreements [Line Items]                  
Revenue from grant               0 $ 0
Grant Agreements | Grants Revenue Receivable                  
Research And Development Collaboration Agreements [Line Items]                  
Reimbursement amounts submitted in excess of amounts received are recorded as receivables       0   $ 0   0  
Cancer Prevention and Research Institute of Texas | CPRIT Agreement                  
Research And Development Collaboration Agreements [Line Items]                  
Product development grant awarded     $ 15,200,000            
Takeda Multi-Target Agreement | Takeda Pharmaceuticals Inc                  
Research And Development Collaboration Agreements [Line Items]                  
Deferred revenue       0   2,600,000   0  
Research and development revenue recognized         $ 2,600,000        
Vertex Collaboration Agreement                  
Research And Development Collaboration Agreements [Line Items]                  
Research and development revenue recognized           14,600,000      
Bristol Myers Squibb Collaboration Agreement                  
Research And Development Collaboration Agreements [Line Items]                  
Upfront payment   $ 70,000,000.0              
Milestone payments receivable if option is exercised   874,500,000              
Transaction price allocated to performance obligations   70,000,000.0              
Deferred revenue, current       32,700,000   32,800,000   32,700,000  
Deferred revenue, non-current       $ 22,700,000   $ 30,700,000   $ 22,700,000  
Bristol Myers Squibb Collaboration Agreement | Sales Milestone                  
Research And Development Collaboration Agreements [Line Items]                  
Milestone payments receivable if option is exercised   $ 450,000,000.0              
Maximum | Takeda Development and License Agreement                  
Research And Development Collaboration Agreements [Line Items]                  
Clinical and regulatory milestone payments $ 22,250,000